文献速递泌尿男性生殖肿瘤

每周对比每3周卡巴他赛治疗去势抵抗性前列腺癌的随机II期试验

Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
PubMed 文献 · Eur J Cancer · 2018-04-21

这项前瞻性多中心II期研究将101例mCRPC患者随机分配至每3周卡巴他赛25 mg/m2组或每周10 mg/m2(6周中5周)组,主要终点为剂量强度。结果显示每周方案未提高18周累积剂量,但发热性中性粒细胞减少发生率更低,而血尿和输尿管炎症更常见。

要点

  • 每周卡巴他赛未提高剂量强度,18周中位累积剂量两组差异无统计学意义(p=0.13)。
  • 每周组发热性中性粒细胞减少事件更少(1 vs 10,p<0.008),但低级别血尿更多(15 vs 5,p=0.003)。
  • 两组PFS和OS无显著差异,每周组有3例发生临床显著的输尿管炎症。

核心结论

  • 每周卡巴他赛降低发热性中性粒细胞减少发生率,但未提高剂量强度。
  • 卡巴他赛在重度经治mCRPC患者中具有临床意义的疗效。

研究设计与样本

  • 前瞻性多中心II期随机试验,纳入101例mCRPC患者。
  • A组为卡巴他赛每3周25 mg/m2,B组为每周10 mg/m2(6周中5周)。
  • 主要终点为剂量强度,假设B组18周相对累积剂量绝对增加20%。

主要发现

  • 18周中位累积剂量A组276 mg(45-320),B组257 mg(20-330),p=0.13。
  • 中位PFS A组6.0个月,B组6.4个月(HR 0.73,95%CI 0.47-1.13,p=0.156)。
  • 中位OS A组14.6个月,B组15.6个月(HR 0.95,95%CI 0.58-1.58,p=0.85)。
  • PSA缓解率(≥50%)A组52%,B组46%。
  • 发热性中性粒细胞减少A组10例,B组1例(p<0.008);低级别血尿A组5例,B组15例(p=0.003)。

关键数值与推荐

  • 每周方案未达到主要终点(18周累积剂量绝对增加20%)。
  • B组更多患者因毒性停止治疗。
  • A组发生1例V级发热性中性粒细胞减少。
  • B组3例出现临床显著的输尿管炎症(卡巴他赛既往未描述的毒性)。

临床怎么用

  • 每周卡巴他赛可作为降低发热性中性粒细胞减少风险的选项,但需监测血尿和输尿管炎症。
  • 标准每3周方案仍是剂量强度上的参考。

局限性

  • II期研究样本量有限(101例),主要终点未达到。
  • 每周方案因毒性停药更多,可能影响剂量强度评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Patients treated with cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) may experience dose delays and reductions or terminate treatment because of toxicity. A lower and more frequent dose of cabazitaxel could improve dose intensity. PATIENTS AND METHODS: This prospective, multi-center, phase II study randomly assigned 101 patients to Arm A, cabazitaxel Q3W, 25 mg/m2 or Arm B, Q1W, 10 mg/m2 5 of 6 weeks. The primary end-point was dose intensity, and we hypothesised that the experimental arm (Arm B) would result in a 20% absolute increase in the relative cumulative dose by week 18. Secondary end-points were overall survival (OS), progression-free survival (PFS), pain progression, radiological and prostate-specific antigen (PSA) response rates, quality of life (Functional Assessment of Cancer Therapy Prostate) and tolerability. RESULTS: Median doses of cabazitaxel were 276 mg (45-320) and 257 mg (20-330) in Arms A and B, respectively, at week 18 (p = 0.13). More patients in Arm B stopped treatment because of toxicity. Median PFS in Arms A and B were 6.0 and 6.4 months (hazard ratio [HR] 0.73, 95% confidence interval [CI]: 0.47-1.13, p = 0.156) and for OS, 14.6 and 15.6 months (HR 0.95, CI: 0.58-1.58, p = 0.85), respectively. PSA responses ≥50% were seen in 52% and 46% of patients in Arms A and B, respectively. A higher incidence of febrile neutropenia was observed in the standard arm (10 events versus 1, p < 0.008). A grade V febrile neutropenia occurred in Arm A. Low-grade haematuria was more prevalent with weekly cabazitaxel (15 events versus 5, p = 0.003). Three patients in Arm B experienced clinically significant inflammation of the ureters. A toxicity is not previously described for cabazitaxel. CONCLUSION: Weekly cabazitaxel reduces the incidence of febrile neutropenia but does not increase the dose intensity compared with the standard therapy. Cabazitaxel has clinical meaningful efficacy in heavily pre-treated patients with mCRPC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yachnin J, Gilje B, Thon K, et al. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab). Eur J Cancer. 2018. PMID: 29685343. doi:10.1016/j.ejca.2018.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。